Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7304 USD | +10.50% | +2.87% | -1.70% |
Business Summary
Number of employees: 55
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Difelikefalin-based Product
100.0
%
| 42 | 100.0 % | 21 | 100.0 % | -49.92% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 42 | 100.0 % | 21 | 100.0 % | -49.92% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 54 | 18-08-05 | |
Ryan Maynard
DFI | Director of Finance/CFO | 54 | 22-09-11 |
Scott Terrillion
CMP | Compliance Officer | 61 | 16-10-31 |
Iris Francesconi
IRC | Investor Relations Contact | - | - |
Beth Weinberg
LAW | General Counsel | - | - |
Richard Makara
AUD | Comptroller/Controller/Auditor | 54 | 14-09-30 |
Eric J. Vandal
PRN | Corporate Officer/Principal | - | 14-06-01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Martin Vogelbaum
CHM | Chairman | 60 | 10-06-30 |
Jeffrey Ives
BRD | Director/Board Member | 73 | 14-07-15 |
Helen Boudreau
BRD | Director/Board Member | 58 | 23-08-01 |
Chief Executive Officer | 54 | 18-08-05 | |
Susan Shiff
BRD | Director/Board Member | 63 | 20-06-25 |
Lisa von Moltke
BRD | Director/Board Member | 65 | 22-10-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 54,656,413 | 46,686,024 ( 85.42 %) | 0 | 85.42 % |
Company contact information
CARA Therapeutics, Inc.
400 Atlantic Street Suite 500
06901, Stamford
+203 406 3700
http://www.caratherapeutics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.70% | 39.93M | |
-2.68% | 85.68B | |
+5.53% | 41.4B | |
-24.99% | 28.22B | |
+54.63% | 24.64B | |
-7.19% | 16.98B | |
-34.20% | 13.29B | |
-17.31% | 11.66B | |
-11.43% | 11.65B | |
-1.57% | 8.18B |
- Stock Market
- Equities
- CARA Stock
- Company Cara Therapeutics, Inc.